107754-20-1 Usage
Description
4-[[5-[[cyclopentyloxy)carbonyl]amino]-1-methylindol-3-yl]methyl]-3-methoxybenzoic acid is a complex organic compound characterized by its off-white solid appearance. It is an intermediate in the synthesis of Zafirlukast (Z125000), a leukotriene antagonist used in the treatment of asthma and other respiratory conditions.
Uses
Used in Pharmaceutical Industry:
4-[[5-[[cyclopentyloxy)carbonyl]amino]-1-methylindol-3-yl]methyl]-3-methoxybenzoic acid is used as an intermediate in the synthesis of Zafirlukast (Z125000) for its role as a leukotriene antagonist. This application is due to its chemical properties that allow it to be a key component in the development of medications that help control asthma and other respiratory issues by blocking the action of leukotrienes, which are chemicals that can cause inflammation in the airways.
Additionally, given its complex structure and potential for interaction with biological targets, further research may reveal additional uses in various pharmaceutical applications, such as the development of new drugs or drug delivery systems. However, these potential uses would require more detailed information and research to confirm.
Check Digit Verification of cas no
The CAS Registry Mumber 107754-20-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,7,7,5 and 4 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 107754-20:
(8*1)+(7*0)+(6*7)+(5*7)+(4*5)+(3*4)+(2*2)+(1*0)=121
121 % 10 = 1
So 107754-20-1 is a valid CAS Registry Number.
InChI:InChI=1/C24H26N2O5/c1-26-14-17(11-15-7-8-16(23(27)28)12-22(15)30-2)20-13-18(9-10-21(20)26)25-24(29)31-19-5-3-4-6-19/h7-10,12-14,19H,3-6,11H2,1-2H3,(H,25,29)(H,27,28)
107754-20-1Relevant articles and documents
Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast
Schierle, Simone,Helmst?dter, Moritz,Schmidt, Jurema,Hartmann, Markus,Horz, Maximiliane,Kaiser, Astrid,Weizel, Lilia,Heitel, Pascal,Proschak, Anna,Hernandez-Olmos, Victor,Proschak, Ewgenij,Merk, Daniel
, p. 50 - 67 (2019/11/29)
The nuclear farnesoid X receptor (FXR) and the enzyme soluble epoxide hydrolase (sEH) are validated molecular targets to treat metabolic disorders such as non-alcoholic steatohepatitis (NASH). Their simultaneous modulation in vivo has demonstrated a triad of anti-NASH effects and thus may generate synergistic efficacy. Here we report dual FXR activators/sEH inhibitors derived from the anti-asthma drug Zafirlukast. Systematic structural optimization of the scaffold has produced favorable dual potency on FXR and sEH while depleting the original cysteinyl leukotriene receptor antagonism of the lead drug. The resulting polypharmacological activity profile holds promise in the treatment of liver-related metabolic diseases.
An improved and scalable process for zafirlukast: An asthma drug
Goverdhan, Gilla,Reddy, Anumula Raghupathi,Sampath, Aalla,Srinivas, Kurella,Himabindu, Vurimidi,Reddy, Ghanta Mahesh
experimental part, p. 67 - 72 (2010/04/22)
An improved and scalable process for the large-scale production of zafirlukast (Accolate), an important drug for asthma, is discussed along with impurity and scale-up-related issues.
PROCESSES FOR PREPARING ZAFIRLUKAST
-
Page/Page column 9, (2009/06/27)
An improved process for the preparation of substantially pure zafirlukast and pharmaceutical compositions thereof.